logo
logo

Twinstrand Biosciences Announces $50 Million Series B To Expand The Adoption Of Its Duplex Sequencing Technology In Applications Requiring The Highest Sensitivity And Accuracy

May 06, 2021•about 4 years ago

Amount Raised

$50 Million

Round Type

series b

Seattle

Description

TwinStrand Biosciences, the pioneer and developer of Duplex Sequencing, an ultra-high accuracy technology for revealing exceptionally low-frequency genetic variants, today announced that it has closed a $50 million Series B financing led by Section 32, with participation from new investors Soleus Capital, Janus Henderson Investors, and existing investors Madrona Venture Group, Ridgeback Capital, and Alexandria Venture Investments, among others. As part of the financing, Michael Pellini, MD, Partner at Section 32, will join the TwinStrand Board of Directors.

Company Information

Company

Twin Strand Biosciences

Location

Seattle, Washington, United States

About

TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods. The company's highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health, and other fields of science on a faster timescale, where actions are most impactful. TwinStrand's scientist-leaders have authored more than two dozen peer-reviewed articles using Duplex Sequencing Technology and have developed a portfolio of more than 100 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.twinstrandbio.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech